Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRIN BD
2024-516584-86-00Phase 2Authorised
- Sponsor
- Institute of Psychiatry and Neurology
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aspirin in bipolar disorder (BD) (2 arms), sponsored by Institute of Psychiatry and Neurology. Primary endpoints: Change in HAMD-17 score at 2 months and Relapse or worsening rates at 4, 6, and 12 months. Planned start Aug 2024; status: authorised.
02
Drugs
aspirin
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2024-516584-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516584-86-00.